Tnf Pharmaceuticals Inc (TNFA)

Apr 22, 2025, 9:15 AM EDT - 5 days ago

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

Apr 16, 2025, 9:15 AM EDT - 11 days ago

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025

Mar 17, 2025, 9:15 AM EDT - 5 weeks ago

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

Mar 5, 2025, 9:00 AM EST - 7 weeks ago

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

Feb 25, 2025, 9:20 AM EST - 2 months ago

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

Jan 29, 2025, 9:15 AM EST - 3 months ago

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

Jan 15, 2025, 9:15 AM EST - 3 months ago

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Dec 19, 2024, 9:15 AM EST - 4 months ago

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

Dec 9, 2024, 9:00 AM EST - 4 months ago

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

Oct 2, 2024, 9:10 AM EDT - 7 months ago

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

Aug 21, 2024, 9:00 AM EDT - 8 months ago

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

Jul 24, 2024, 9:05 AM EDT - 9 months ago

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

Jul 22, 2024, 9:00 AM EDT - 9 months ago

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

Jun 17, 2024, 9:00 AM EDT - 11 months ago

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

May 21, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Secures Strategic Investments

PMCB

May 21, 2024, 9:00 AM EDT - 1 year ago

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

PMCB

Mar 5, 2024, 9:15 AM EST - 1 year ago

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Feb 13, 2024, 11:45 AM EST - 1 year ago

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

Dec 29, 2023, 12:45 PM EST - 1 year ago

MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug

Dec 6, 2023, 9:15 AM EST - 1 year ago

MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

Oct 19, 2023, 9:00 AM EDT - 1 year ago

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

Oct 4, 2023, 7:30 AM EDT - 1 year ago

MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023

Aug 14, 2023, 8:30 AM EDT - 1 year ago

FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)

Aug 2, 2023, 8:30 AM EDT - 1 year ago

MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

Jul 31, 2023, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

Apr 12, 2023, 8:30 AM EDT - 2 years ago

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Mar 20, 2023, 8:55 AM EDT - 2 years ago

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

Mar 8, 2023, 8:30 AM EST - 2 years ago

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

Mar 2, 2023, 8:30 AM EST - 2 years ago

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

Feb 28, 2023, 8:30 AM EST - 2 years ago

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

Feb 21, 2023, 8:45 AM EST - 2 years ago

MyMD Announces $15 Million Offering with Existing Investors

Dec 6, 2022, 9:40 AM EST - 2 years ago

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Dec 6, 2022, 8:00 AM EST - 2 years ago

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Nov 17, 2022, 8:00 AM EST - 2 years ago

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

Nov 14, 2022, 8:00 AM EST - 2 years ago

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

Aug 30, 2022, 8:30 AM EDT - 2 years ago

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound

Aug 3, 2022, 9:45 AM EDT - 2 years ago

Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

Jul 26, 2022, 7:30 AM EDT - 2 years ago

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Jul 12, 2022, 9:30 AM EDT - 3 years ago

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

Jun 21, 2022, 10:30 AM EDT - 3 years ago

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Apr 12, 2022, 9:30 AM EDT - 3 years ago

MyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

Apr 5, 2022, 9:15 AM EDT - 3 years ago

MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Mar 24, 2022, 9:26 AM EDT - 3 years ago

MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24

Feb 23, 2022, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Feb 8, 2022, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Jan 5, 2022, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

Dec 29, 2021, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

ORMP

Dec 1, 2021, 10:05 AM EST - 3 years ago

MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021